UPDATE: The webinar video is now available along with a program website featuring FAQs.

As part of NIH’s UNITE initiative to promote diversity, equity, and inclusion in biomedical research, we’re pleased to announce the release of the notice of funding opportunity (NOFO): Instrumentation Grant Program for Resource-Limited Institutions (RLI-S10) (PAR-23-138). The RLI-S10 program aims to enhance research capacity and educational opportunities at resource-limited institutions by providing funds to purchase modern, scientific instrumentation. Applications may propose purchase of instruments that support basic, translational, clinical, or biomedically related behavioral science. The instruments may be used in formal courses for teaching purposes as well as for research projects.

I’m pleased to announce the selection of Shawn Drew Gaillard, Ph.D., as the new director of our Division of Genetics and Molecular, Cellular, and Developmental Biology (GMCDB). Shawn has been the acting director of the Division since February 2022. She will begin in this new role on January 15.

Shawn joined GMCDB as chief of the Developmental and Cellular Processes Branch in 2019, overseeing grants focused on organismal response to environmental stressors. Prior to this role, she was the research training officer at the National Institute of Allergy and Infectious Diseases, and before that, she was a program director in our Division of Training, Workforce Development, and Diversity and former Division of Genetics and Developmental Biology. Her experience also includes serving as a science education fellow at the Howard Hughes Medical Institute and directing what is now the NIH Academy on Health Disparities.

Since the Medical Scientist Training Program (MSTP) began in 1975, it has supported more than 14,000 clinician-scientist trainees. The program provides predoctoral training grants (T32) to institutions to develop and implement effective, evidence-informed training for students pursuing both a clinical and a research doctorate degree (i.e., M.D.-Ph.D.).

NIGMS maintains a diverse biomedical research portfolio, supporting a wide range of topics and investigators. In Fiscal Year (FY) 2021, NIGMS received a congressional appropriation of $2,991,417,000. As part of the Consolidated Appropriations Act, 2022, this budget increased by 3.4% to $3,092,373,000 for FY 2022. The majority of these funds support research project grants (RPGs) at research institutions throughout the country. In alignment with its commitment to transparency, NIGMS publishes data on annual trends in its grants portfolio. In this post, we first describe investigator-level trends for RPGs, then review the trends associated with competing RPGs, and lastly examine trends in the Institute’s Maximizing Investigators’ Research Award (MIRA) program.

NIGMS’ Maximizing Investigators’ Research Award (MIRA) provides investigators with flexibility and stability for their research programs. Investigators who receive MIRA support must dedicate 51% of their research effort toward the grant and are ineligible to apply for or receive other NIGMS research support (with some exceptions). One question frequently asked is whether the NIGMS funding restriction changes the likelihood that MIRA grantees will submit applications to other NIH institutes and centers (ICs). In this post, we compare data on post-award grant applications from NIGMS-funded investigators.

To compare application behavior between MIRA and R01-funded investigators, we created sets of both established (EI) and early stage (ESI) investigators supported by NIGMS R01s (called the comparator group) who have not received a MIRA. The EI comparators were matched according to race/ethnicity, gender, time since acquisition of first R01, and average annual NIGMS funding. For the ESI comparator group, we used all ESI NIGMS R01 awardees.

NIGMS funded its first round of renewals for the Maximizing Investigators’ Research Award (MIRA) program in Fiscal Year (FY) 2021. In this post, we compare data on the award rates and award sizes of MIRA renewals and R01 renewals to provide some insights into the early outcomes of MIRA renewals. We also examine award rates and budget changes for investigators applying to convert their NIGMS R01s to MIRAs.

In the first section, we present award rates (the percentage of reviewed applications that receive funding), considering both programs overall and then FY 2021 renewal applications specifically. The second section describes the award sizes for the two types of grants collectively, followed by award size changes for FY 2021 renewals. Where sample sizes and privacy concerns allow, we distinguish between established investigators (EIs) and early stage investigators (ESIs) renewing their first grants (“ex-ESIs”) as they often have different characteristics for award rates and sizes. All budget values shown in the post are yearly direct costs.

I’m pleased to share that Dorit Zuk has been selected as NIGMS’ new deputy director.

Dorit has been a vital member of the NIGMS leadership team for many years, including serving as acting deputy director for the past year, and as director of our Division of Genetics and Molecular, Cellular, and Developmental Biology since January 2016. During her tenure at NIGMS, she’s made valuable contributions to our 2021-2025 strategic plan and reorganization of the Institute’s divisions in 2018, and has led efforts to build a stronger, more diverse, and collaborative workforce—both within NIGMS and beyond.

Please join me in congratulating Dorit on her selection for this position. We can all look forward to benefitting from her continued leadership.

UPDATE: The videocast of the ARPA-H session on August 4 is now available.

President Biden recently called for the establishment of the Advanced Research Projects Agency for Health (ARPA-H) to improve our capabilities to speed research that can improve the health of all Americans. The proposed mission of ARPA-H could include investments in breakthrough technologies and broadly applicable platforms, resources, and solutions that can’t be readily accomplished through traditional research or commercial activity. Such innovations could transform important areas of medicine and health for the benefit of all patients.

I’m pleased to announce the release of the NIGMS 2021-2025 Strategic Plan. Like its predecessor, this plan sets the direction and priorities that the Institute will pursue over the next 5 years. It enumerates a series of goals, objectives, and implementation strategies that build upon the successful outcomes of our prior plan, and it reflects key organizational values of the Institute. The plan also contains representative targets for each implementation strategy that promote both transparency and accountability to ensure that progress is tracked and periodically reported, and that any necessary course corrections can be implemented.

On December 27, 2020, the Consolidated Appropriations Act, 2021, was signed into law. The appropriation provides NIGMS with a budget of $2,991,417,000, in Fiscal Year (FY) 2021, a 1.8% increase over the FY 2020 appropriation. With this increased budget, NIGMS is committed to providing taxpayers with the best possible returns on their investments in fundamental biomedical research. As part of this commitment to stewardship, we regularly monitor trends in our funding portfolio.

NIGMS maintains a diversified biomedical research portfolio, supporting a wide range of topics and investigators. NIGMS and NIH programs and policies aim to increase the number of funded investigators and to maintain researchers’ funding stability over time. In this post, we describe NIGMS investigator-level trends for selected R01-equivalent grants as well as overall research project grant (RPG) trends for FY 2020 compared to previous fiscal years.